XOMA Corp. (XOMA) Initiates Phase 3 for Gevokizumab
XOMA Corporation (Nasdaq: XOMA) today announced it has opened enrollment in two clinical trials to determine gevokizumab's potential to treat interleukin-1 beta-mediated inflammatory diseases. The first trial is XOMA's global Phase 3 study investigating the ability of gevokizumab to reduce the signs and symptoms, including vitreous haze, in patients with non-infectious uveitis (NIU) involving the intermediate and/or posterior segment of the eye. The second trial is a Phase 2 study to evaluate the potential for gevokizumab to improve pain symptoms, physical function and structural abnormalities in patients with erosive osteoarthritis of the hand. Patients currently are being screened in both trials.
You May Also Be Interested In
- UPDATE: ImmunoCellular (IMUC) Phase II Study Does Not Meet Survival Endpoint
- Sanofi's (SNY) Genzyme Granted FDA Priority Review for Cerdelga NDA
- Gentium (GENT) Updates on Additional Defibrotide Data at ASH
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!